Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.
Antoine AdenisFrançois GhiringhelliLudovic GauthierThibault MazardLudovic EvesqueAlexandre EvrardPatrick ChalbosAurore MoussionSophie GourgouMarc YchouPublished in: Cancer chemotherapy and pharmacology (2024)
ClinicalTrials.gov : NCT03828799.